RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE CURRENT STATE OF PLAY
Multiple myeloma (MM) usually responds to treatment but is incurable. The clinical course is characterised, in most patients, by a series of remissions and relapses. For younger patients, the initial treatment currently usually involves induction with the proteasome inhibitor bortezomib (BOR), alone...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2015-07-01
|
| Series: | European Medical Journal Hematology |
| Subjects: | |
| Online Access: | https://emj.emg-health.com/wp-content/uploads/sites/2/2018/02/RelapsedRefractory-Multiple-Myeloma-The-Current-State-of-Play1.pdf |
| _version_ | 1811297110058860544 |
|---|---|
| author | María-Victoria Mateos Enrique M. Ocio Verónica González Julio Dávila |
| author_facet | María-Victoria Mateos Enrique M. Ocio Verónica González Julio Dávila |
| author_sort | María-Victoria Mateos |
| collection | DOAJ |
| description | Multiple myeloma (MM) usually responds to treatment but is incurable. The clinical course is characterised, in most patients, by a series of remissions and relapses. For younger patients, the initial treatment currently usually involves induction with the proteasome inhibitor bortezomib (BOR), alone or in combination, followed by an autologous stem cell transplant (ASCT). Usually only clinical relapses require treatment; the treatment plan should be individualised to take into account factors such as response to previous treatment, duration of the remission, adverse effects experienced, and available treatment options. Evidence suggests that many patients who have responded to BOR will respond to it again. Patients at first relapse should also be considered for a further ASCT or an allotransplant. Clinical studies have led to other drugs being approved for treatment of relapsed MM. These include lenalidomide (an immunomodulatory drug), carfilzomib (another proteasome inhibitor), pomalidomide (an immunomodulatory drug), and most recently panobinostat (a deacetylase inhibitor). The availability of these drugs greatly enhances the therapeutic options available to treat further relapses. Moreover, a bewildering array of other novel agents are at various stages in testing. They include other drugs from the classes already mentioned, as well as monoclonal antibodies, drugs acting on the cell cycle, kinase inhibitors, and signal transduction pathway inhibitors. It seems probable that the introduction of these agents in the coming years will further improve the survival of patients with MM, and may even lead to a cure. |
| first_indexed | 2024-04-13T05:58:20Z |
| format | Article |
| id | doaj.art-1cfc286f84124580b08c7b2370ac7870 |
| institution | Directory Open Access Journal |
| issn | 2053-6631 |
| language | English |
| last_indexed | 2024-04-13T05:58:20Z |
| publishDate | 2015-07-01 |
| publisher | European Medical Journal |
| record_format | Article |
| series | European Medical Journal Hematology |
| spelling | doaj.art-1cfc286f84124580b08c7b2370ac78702022-12-22T02:59:31ZengEuropean Medical JournalEuropean Medical Journal Hematology2053-66312015-07-01RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE CURRENT STATE OF PLAYMaría-Victoria Mateos0Enrique M. Ocio1Verónica González2Julio Dávila3University Hospital of Salamanca/IBSAL, Salamanca, SpainUniversity Hospital of Salamanca/IBSAL, Salamanca, SpainUniversity Hospital of Salamanca/IBSAL, Salamanca, SpainUniversity Hospital of Salamanca/IBSAL, Salamanca, SpainMultiple myeloma (MM) usually responds to treatment but is incurable. The clinical course is characterised, in most patients, by a series of remissions and relapses. For younger patients, the initial treatment currently usually involves induction with the proteasome inhibitor bortezomib (BOR), alone or in combination, followed by an autologous stem cell transplant (ASCT). Usually only clinical relapses require treatment; the treatment plan should be individualised to take into account factors such as response to previous treatment, duration of the remission, adverse effects experienced, and available treatment options. Evidence suggests that many patients who have responded to BOR will respond to it again. Patients at first relapse should also be considered for a further ASCT or an allotransplant. Clinical studies have led to other drugs being approved for treatment of relapsed MM. These include lenalidomide (an immunomodulatory drug), carfilzomib (another proteasome inhibitor), pomalidomide (an immunomodulatory drug), and most recently panobinostat (a deacetylase inhibitor). The availability of these drugs greatly enhances the therapeutic options available to treat further relapses. Moreover, a bewildering array of other novel agents are at various stages in testing. They include other drugs from the classes already mentioned, as well as monoclonal antibodies, drugs acting on the cell cycle, kinase inhibitors, and signal transduction pathway inhibitors. It seems probable that the introduction of these agents in the coming years will further improve the survival of patients with MM, and may even lead to a cure.https://emj.emg-health.com/wp-content/uploads/sites/2/2018/02/RelapsedRefractory-Multiple-Myeloma-The-Current-State-of-Play1.pdfmultiple myeloma (mm)relapseproteasome inhibitorimmunomodulatormonoclonal antibodydeacetylase inhibitor |
| spellingShingle | María-Victoria Mateos Enrique M. Ocio Verónica González Julio Dávila RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE CURRENT STATE OF PLAY European Medical Journal Hematology multiple myeloma (mm) relapse proteasome inhibitor immunomodulator monoclonal antibody deacetylase inhibitor |
| title | RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE CURRENT STATE OF PLAY |
| title_full | RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE CURRENT STATE OF PLAY |
| title_fullStr | RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE CURRENT STATE OF PLAY |
| title_full_unstemmed | RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE CURRENT STATE OF PLAY |
| title_short | RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE CURRENT STATE OF PLAY |
| title_sort | relapsed refractory multiple myeloma the current state of play |
| topic | multiple myeloma (mm) relapse proteasome inhibitor immunomodulator monoclonal antibody deacetylase inhibitor |
| url | https://emj.emg-health.com/wp-content/uploads/sites/2/2018/02/RelapsedRefractory-Multiple-Myeloma-The-Current-State-of-Play1.pdf |
| work_keys_str_mv | AT mariavictoriamateos relapsedrefractorymultiplemyelomathecurrentstateofplay AT enriquemocio relapsedrefractorymultiplemyelomathecurrentstateofplay AT veronicagonzalez relapsedrefractorymultiplemyelomathecurrentstateofplay AT juliodavila relapsedrefractorymultiplemyelomathecurrentstateofplay |